OC- 27- 0 525 Rec'd PCT/PTC 28

PTO/SB/21 (08-00)

type a plus sign (+) inside this box - +

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

#### **Application Number** 09/673,958 TRANSMITTAL August 13, Filing Date **FORM** M. NANBA First Named Inventor (to be used for all correspondence after initial filing) Group Art Unit 1645 tba **Examiner Name** 2519 US0P Total Number of Pages in This Submission 7 Attorney Docket Number **ENCLOSURES** (check all that apply) **Assignment Papers** After Allowance Communication Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Licensing-related Papers Appeal Communication to Group Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition After Final Proprietary Information Petition to Convert to a Affidavits/declaration(s) Provisional Application Status Letter Power of Attorney, Revocation Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request identify below): Terminal Disclaimer Return Postcard. **Express Abandonment Request** Certificate of Express Mailing Request for Refund Request to Correct Filing Receipt Copy of Filing Receipt Information Disclosure Statement CD, Number of CD(s) -Certified Copy of Priority Document(s) The Commissioner is hereby authorized to Remarks charge any additional fees which may be Response to Missing Parts/ Incomplete Application required, or credit any overpayment to Response to Missing Parts Deposit Account 500799. under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Mark Chao Ph.D., JD, Reg. No 37,293 Individual name Signature Date **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Residences mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 6 | 26/02 Gail L. Winokur Typed or printed name

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

12/2

Signature

Express Mail # EV 082675418 45

Date

THE UNITED STATES PATENT AND TRADEMARK OFFICE

plication No.:

09/673,958

Filed:

August 13, 2001

1<sup>st</sup> Inventor:

M. NANBA

For:

Human Derived Immortalized Liver Cell Line

Atty. Dkt. No.

2519 US0P

Art Unit:

1645

tba

Examiner:

Allowed:

Batch:

Paper No.:

## **CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

USPS EXPRESS MAIL LABEL. No. EV 082675418 US

DATE IN:

June 26, 2002

RECEIVED

JUL 1 7 2002

## Itemized Papers/Items:

`

TECH CENTER 1600/2900

- 1. This certificate and a Return Receipt Postcard (2 pgs.)
- 2. Transmittal Form (1 pg. X 2)
- 3. Request to Correct Filing Receipt, and copy of Filing Receipt (3 pgs.)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231.

on this date, 6/26/02

Dated: 6/26/02

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

09/673,958

Filed:

August 13, 2001

1<sup>st</sup> Inventor:

M. NANBA

For:

Human Derived Immortalized Liver Cell Line

Atty. Dkt. No.

2519 US0P

Art Unit:

1645

tba

Examiner:

Allowed:

Batch:

D.... > 1

Paper No.:

## REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Sir:

Applicants request that a corrected Filing Receipt be issued for the above-identified case correcting the misspelling of inventor Nanba's first name, and correcting the typographical error in the title of the invention.

Please correct the spelling of inventor Nanba's first name to read as follows:

--Masayoshi Nanba--

Please rewrite the title of the invention to read as follows:

-- HUMAN DERIVED IMMORTALIZED LIVER CELL LINE --

A copy of the Filing Receipt is enclosed showing the correction.

If there are any questions, please call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: 6/26/02

(847) 383-3372

(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA



## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/673,958	08/13/2001	1645	1230	2519US0P	5	11	1

**CONFIRMATION NO. 8993** 

23115
TAKEDA PHARMACEUTICALS NORTH AMERICA, INC
INTELLECTUAL PROPERTY DEPARTMENT

475 HALF DAY ROAD SUITE 500

SUITE 500 LINCOLNSHIRE, IL 60069 REPLACEMENT FILING RECEIPT

\*OC000000008329278\*

Date Mailed: 06/21/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) -- Masayoshi --

[Nasayeshi] Nanba, Okayama, JAPAN; Kenichi Fukaya, Katsuyama-shi, JAPAN; Satoru Asahi, Osaka, JAPAN; Sumie Yoshitomi, Osaka, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/02224 04/27/1999

**Foreign Applications** 

JAPAN 10-119394 04/28/1998

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

Title

Human deriven immortalized liver cell line
--derived--



435

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

## **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).